Hit by tri­al set­back, Aslan slash­es staff and a study — hun­ker­ing down in wait for piv­otal da­ta

Two weeks af­ter re­port­ing the fail­ure of a key Phase II study of their lead drug, Aslan Phar­ma­ceu­ti­cals $ASLN is re­struc­tur­ing, slash­ing staff and shut­ter­ing a tri­al as they aim for a piv­otal win.

Out the ex­it goes Bertil Lind­mark, the chief med­ical of­fi­cer, now head­ed back to Eu­rope. The CMO is leav­ing with 30% of the staff as the biotech slash­es its burn rate in half. In oth­er staff moves Chih-Yi Hsieh, the VP Med­ical and GM Tai­wan, will take the role of act­ing CMO while COO Mark McHale be­comes head of R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.